Related Experiment Videos

[Distribution of 4-14C-mofebutazone in the rat]

Insights

Mofebutazone rapidly distributes to elimination organs and is quickly excreted, with nearly 81% eliminated in 24 hours. This rapid excretion prevents drug accumulation in rats, suggesting a low risk of toxicity.

Area of Science:

  • Pharmacokinetics
  • Drug Metabolism
  • Toxicology

Background:

  • Mofebutazone and phenylbutazone are nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Understanding mofebutazone's distribution and elimination is crucial for assessing its safety profile.
  • Comparative pharmacokinetic data between mofebutazone and phenylbutazone is limited.

Purpose of the Study:

  • To investigate the distribution and elimination of mofebutazone in rats.
  • To compare the pharmacokinetic profile of mofebutazone with phenylbutazone.
  • To determine the potential for mofebutazone accumulation in tissues.

Main Methods:

  • Administered 4-14C-mofebutazone (200 mg/kg) to 6 rats.
  • Measured plasma levels and urinary excretion of radioactivity at 45 min, 6 h, and 24 h.
  • Utilized whole-body autoradiography to visualize tissue distribution.

Main Results:

  • Mofebutazone primarily distributed to metabolization and elimination organs.
  • Moderate radioactivity detected in skin and muscle tissue; none in CNS or bone marrow.
  • Nearly 81% of the dose was eliminated within 24 hours, mainly via urine.
  • Autoradiograms showed minimal residual activity after 24 hours, except in the colon.

Conclusions:

  • Mofebutazone exhibits rapid elimination and a short half-life in rats.
  • The drug does not appear to accumulate in tissues, indicating a favorable safety profile.
  • These findings suggest a lower risk of toxicity compared to drugs with longer elimination times.

Related Concept Videos